IART Quote, Financials, Valuation and Earnings

Intuitive Surgical has a net margin of 4.39% compared to Integra Lifesciences Holdings's net margin of 28.41%. Integra Lifesciences Holdings's return on equity of -0.45% beat Intuitive Surgical's return on equity of 15.6%.

Integra Lifesciences Holdings has a consensus price target of $25.63, signalling upside risk potential of 33.53%. On the other hand Intuitive Surgical has an analysts' consensus of $619.74 which suggests that it could grow by 18.51%. Given that Integra Lifesciences Holdings has higher upside potential than Intuitive Surgical, analysts believe Integra Lifesciences Holdings is more attractive than Intuitive Surgical.

Integra Lifesciences Holdings has a beta of 1.241, which suggesting that the stock is 24.12% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.555, suggesting its more volatile than the S&P 500 by 55.506%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Integra Lifesciences Holdings quarterly revenues are $442.6M, which are smaller than Intuitive Surgical quarterly revenues of $2.4B. Integra Lifesciences Holdings's net income of $19.4M is lower than Intuitive Surgical's net income of $685.7M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Intuitive Surgical's PE ratio is 81.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.92x versus 22.67x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

LeMaitre Vascular has a net margin of 4.39% compared to Integra Lifesciences Holdings's net margin of 20.07%. Integra Lifesciences Holdings's return on equity of -0.45% beat LeMaitre Vascular's return on equity of 13.81%.

Integra Lifesciences Holdings has a consensus price target of $25.63, signalling upside risk potential of 33.53%. On the other hand LeMaitre Vascular has an analysts' consensus of $105.63 which suggests that it could grow by 25.89%. Given that Integra Lifesciences Holdings has higher upside potential than LeMaitre Vascular, analysts believe Integra Lifesciences Holdings is more attractive than LeMaitre Vascular.

Integra Lifesciences Holdings has a beta of 1.241, which suggesting that the stock is 24.12% more volatile than S&P 500. In comparison LeMaitre Vascular has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.293%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LeMaitre Vascular offers a yield of 0.81% to investors and pays a quarterly dividend of $0.20 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. LeMaitre Vascular pays out 32.65% of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Integra Lifesciences Holdings quarterly revenues are $442.6M, which are larger than LeMaitre Vascular quarterly revenues of $55.7M. Integra Lifesciences Holdings's net income of $19.4M is higher than LeMaitre Vascular's net income of $11.2M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while LeMaitre Vascular's PE ratio is 43.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.92x versus 8.69x for LeMaitre Vascular. Usually stocks with elevated PS ratios are considered overvalued.

Orthofix Medical has a net margin of 4.39% compared to Integra Lifesciences Holdings's net margin of -13.52%. Integra Lifesciences Holdings's return on equity of -0.45% beat Orthofix Medical's return on equity of -22.96%.

Integra Lifesciences Holdings has a consensus price target of $25.63, signalling upside risk potential of 33.53%. On the other hand Orthofix Medical has an analysts' consensus of $24.30 which suggests that it could grow by 65.08%. Given that Orthofix Medical has higher upside potential than Integra Lifesciences Holdings, analysts believe Orthofix Medical is more attractive than Integra Lifesciences Holdings.

Integra Lifesciences Holdings has a beta of 1.241, which suggesting that the stock is 24.12% more volatile than S&P 500. In comparison Orthofix Medical has a beta of 0.992, suggesting its less volatile than the S&P 500 by 0.759%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orthofix Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Orthofix Medical pays out -- of its earnings as a dividend.

Integra Lifesciences Holdings quarterly revenues are $442.6M, which are larger than Orthofix Medical quarterly revenues of $215.7M. Integra Lifesciences Holdings's net income of $19.4M is higher than Orthofix Medical's net income of -$29.1M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Orthofix Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.92x versus 0.70x for Orthofix Medical. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex has a net margin of 4.39% compared to Integra Lifesciences Holdings's net margin of -17.18%. Integra Lifesciences Holdings's return on equity of -0.45% beat Teleflex's return on equity of 1.57%.

Integra Lifesciences Holdings has a consensus price target of $25.63, signalling upside risk potential of 33.53%. On the other hand Teleflex has an analysts' consensus of $165.22 which suggests that it could grow by 22.24%. Given that Integra Lifesciences Holdings has higher upside potential than Teleflex, analysts believe Integra Lifesciences Holdings is more attractive than Teleflex.

Integra Lifesciences Holdings has a beta of 1.241, which suggesting that the stock is 24.12% more volatile than S&P 500. In comparison Teleflex has a beta of 1.191, suggesting its more volatile than the S&P 500 by 19.095%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex offers a yield of 1.01% to investors and pays a quarterly dividend of $0.34 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Integra Lifesciences Holdings quarterly revenues are $442.6M, which are smaller than Teleflex quarterly revenues of $795.4M. Integra Lifesciences Holdings's net income of $19.4M is higher than Teleflex's net income of -$136.7M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Teleflex's PE ratio is 95.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.92x versus 2.09x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.